Voriconazole exposure and risk of cutaneous squamous cell carcinoma among lung or hematopoietic cell transplant patients: A systematic review and meta-analysis

Huilin Tang, Weilong Shi, Yiqing Song, Jiali Han

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Current evidence about the association between voriconazole and risk of cutaneous squamous cell carcinoma (SCC) remains inconsistent. Objective: To assess the association between voriconazole use and risk of SCC. Methods: We systematically searched PubMed and Embase and performed a random effects model meta-analysis to calculate the pooled relative risk (RR) with a 95% confidence interval (CI). Results: Of the 8 studies involving a total of 3710 individuals with a lung transplant or hematopoietic cell transplant that were included in the qualitative analysis, 5 were included in the meta-analysis. Use of voriconazole was significantly associated with increased risk of SCC (RR, 1.86; 95% CI, 1.36-2.55). The increased risk did not differ according to type of transplantation or adjustment for sun exposure. Longer duration of voriconazole use was found to be positively associated with risk of SCC (RR, 1.72; 95% CI, 1.09-2.72). Voriconazole use was not associated with increased risk of basal cell carcinoma (RR, 0.84; 95% CI, 0.41-1.71). Limitations: There were some heterogeneities in the retrospective observational studies. Conclusions: Our findings support an increased risk of SCC associated with voriconazole in individuals with a lung transplant or hematopoietic cell transplant. Routine dermatologic surveillance should be performed, especially among individuals at high risk of developing SCC.

Original languageEnglish (US)
JournalJournal of the American Academy of Dermatology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Meta-Analysis
Squamous Cell Carcinoma
Transplants
Lung
Skin
Confidence Intervals
Voriconazole
Basal Cell Carcinoma
Solar System
PubMed
Observational Studies
Retrospective Studies
Transplantation

Keywords

  • meta-analysis
  • squamous cell carcinoma
  • transplantation
  • voriconazole

ASJC Scopus subject areas

  • Dermatology

Cite this

@article{9bae81ddffde46faa61a89692bfbdeea,
title = "Voriconazole exposure and risk of cutaneous squamous cell carcinoma among lung or hematopoietic cell transplant patients: A systematic review and meta-analysis",
abstract = "Background: Current evidence about the association between voriconazole and risk of cutaneous squamous cell carcinoma (SCC) remains inconsistent. Objective: To assess the association between voriconazole use and risk of SCC. Methods: We systematically searched PubMed and Embase and performed a random effects model meta-analysis to calculate the pooled relative risk (RR) with a 95{\%} confidence interval (CI). Results: Of the 8 studies involving a total of 3710 individuals with a lung transplant or hematopoietic cell transplant that were included in the qualitative analysis, 5 were included in the meta-analysis. Use of voriconazole was significantly associated with increased risk of SCC (RR, 1.86; 95{\%} CI, 1.36-2.55). The increased risk did not differ according to type of transplantation or adjustment for sun exposure. Longer duration of voriconazole use was found to be positively associated with risk of SCC (RR, 1.72; 95{\%} CI, 1.09-2.72). Voriconazole use was not associated with increased risk of basal cell carcinoma (RR, 0.84; 95{\%} CI, 0.41-1.71). Limitations: There were some heterogeneities in the retrospective observational studies. Conclusions: Our findings support an increased risk of SCC associated with voriconazole in individuals with a lung transplant or hematopoietic cell transplant. Routine dermatologic surveillance should be performed, especially among individuals at high risk of developing SCC.",
keywords = "meta-analysis, squamous cell carcinoma, transplantation, voriconazole",
author = "Huilin Tang and Weilong Shi and Yiqing Song and Jiali Han",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jaad.2018.08.010",
language = "English (US)",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Voriconazole exposure and risk of cutaneous squamous cell carcinoma among lung or hematopoietic cell transplant patients

T2 - A systematic review and meta-analysis

AU - Tang, Huilin

AU - Shi, Weilong

AU - Song, Yiqing

AU - Han, Jiali

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Current evidence about the association between voriconazole and risk of cutaneous squamous cell carcinoma (SCC) remains inconsistent. Objective: To assess the association between voriconazole use and risk of SCC. Methods: We systematically searched PubMed and Embase and performed a random effects model meta-analysis to calculate the pooled relative risk (RR) with a 95% confidence interval (CI). Results: Of the 8 studies involving a total of 3710 individuals with a lung transplant or hematopoietic cell transplant that were included in the qualitative analysis, 5 were included in the meta-analysis. Use of voriconazole was significantly associated with increased risk of SCC (RR, 1.86; 95% CI, 1.36-2.55). The increased risk did not differ according to type of transplantation or adjustment for sun exposure. Longer duration of voriconazole use was found to be positively associated with risk of SCC (RR, 1.72; 95% CI, 1.09-2.72). Voriconazole use was not associated with increased risk of basal cell carcinoma (RR, 0.84; 95% CI, 0.41-1.71). Limitations: There were some heterogeneities in the retrospective observational studies. Conclusions: Our findings support an increased risk of SCC associated with voriconazole in individuals with a lung transplant or hematopoietic cell transplant. Routine dermatologic surveillance should be performed, especially among individuals at high risk of developing SCC.

AB - Background: Current evidence about the association between voriconazole and risk of cutaneous squamous cell carcinoma (SCC) remains inconsistent. Objective: To assess the association between voriconazole use and risk of SCC. Methods: We systematically searched PubMed and Embase and performed a random effects model meta-analysis to calculate the pooled relative risk (RR) with a 95% confidence interval (CI). Results: Of the 8 studies involving a total of 3710 individuals with a lung transplant or hematopoietic cell transplant that were included in the qualitative analysis, 5 were included in the meta-analysis. Use of voriconazole was significantly associated with increased risk of SCC (RR, 1.86; 95% CI, 1.36-2.55). The increased risk did not differ according to type of transplantation or adjustment for sun exposure. Longer duration of voriconazole use was found to be positively associated with risk of SCC (RR, 1.72; 95% CI, 1.09-2.72). Voriconazole use was not associated with increased risk of basal cell carcinoma (RR, 0.84; 95% CI, 0.41-1.71). Limitations: There were some heterogeneities in the retrospective observational studies. Conclusions: Our findings support an increased risk of SCC associated with voriconazole in individuals with a lung transplant or hematopoietic cell transplant. Routine dermatologic surveillance should be performed, especially among individuals at high risk of developing SCC.

KW - meta-analysis

KW - squamous cell carcinoma

KW - transplantation

KW - voriconazole

UR - http://www.scopus.com/inward/record.url?scp=85054425726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054425726&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2018.08.010

DO - 10.1016/j.jaad.2018.08.010

M3 - Article

C2 - 30130598

AN - SCOPUS:85054425726

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

ER -